Cargando…
Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
Vernal keratoconjunctivitis (VKC) is a rare, recurrent and multifactorial ocular disease, which typically flares up during spring and affects especially male children and adolescents. This condition does not usually respond to common treatments with antihistamines or mast cells stabilizers, whereas...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616155/ https://www.ncbi.nlm.nih.gov/pubmed/31308622 http://dx.doi.org/10.2147/OPTH.S181811 |
_version_ | 1783433454971518976 |
---|---|
author | Nebbioso, Marcella Alisi, Ludovico Giovannetti, Francesca Armentano, Marta Lambiase, Alessandro |
author_facet | Nebbioso, Marcella Alisi, Ludovico Giovannetti, Francesca Armentano, Marta Lambiase, Alessandro |
author_sort | Nebbioso, Marcella |
collection | PubMed |
description | Vernal keratoconjunctivitis (VKC) is a rare, recurrent and multifactorial ocular disease, which typically flares up during spring and affects especially male children and adolescents. This condition does not usually respond to common treatments with antihistamines or mast cells stabilizers, whereas corticosteroids have effective results. Corticosteroids need to be carefully administered, to avoid adverse effects, mainly the secondary development of glaucoma, cataracts, or infections. Immunosuppressive agents, such as cyclosporin (CyA) or tacrolimus are, therefore, frequently employed in VKC patients. Only the 0.1% CyA (1 mg/mL) concentration has an approved and specific clinical indication for the treatment of VKC and this drug was given the denomination of orphan drug by the European Commission (EU/3/06/360) in 2006. So far, few studies have been conducted to evaluate the efficacy and the side effects of topical 0.1% CyA. Different topical CyA concentrations, ranging from 0.05% to 2%, and various types of formulation are available at the moment. In the future, 0.1% CyA will presumably take an important part in the management of VKC. The present review focuses on eye drops containing 0.1% CyA; however, more studies will be needed to define its long-term efficacy in the natural course of this severe ocular disease. |
format | Online Article Text |
id | pubmed-6616155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66161552019-07-15 Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy Nebbioso, Marcella Alisi, Ludovico Giovannetti, Francesca Armentano, Marta Lambiase, Alessandro Clin Ophthalmol Review Vernal keratoconjunctivitis (VKC) is a rare, recurrent and multifactorial ocular disease, which typically flares up during spring and affects especially male children and adolescents. This condition does not usually respond to common treatments with antihistamines or mast cells stabilizers, whereas corticosteroids have effective results. Corticosteroids need to be carefully administered, to avoid adverse effects, mainly the secondary development of glaucoma, cataracts, or infections. Immunosuppressive agents, such as cyclosporin (CyA) or tacrolimus are, therefore, frequently employed in VKC patients. Only the 0.1% CyA (1 mg/mL) concentration has an approved and specific clinical indication for the treatment of VKC and this drug was given the denomination of orphan drug by the European Commission (EU/3/06/360) in 2006. So far, few studies have been conducted to evaluate the efficacy and the side effects of topical 0.1% CyA. Different topical CyA concentrations, ranging from 0.05% to 2%, and various types of formulation are available at the moment. In the future, 0.1% CyA will presumably take an important part in the management of VKC. The present review focuses on eye drops containing 0.1% CyA; however, more studies will be needed to define its long-term efficacy in the natural course of this severe ocular disease. Dove 2019-07-05 /pmc/articles/PMC6616155/ /pubmed/31308622 http://dx.doi.org/10.2147/OPTH.S181811 Text en © 2019 Nebbioso et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Nebbioso, Marcella Alisi, Ludovico Giovannetti, Francesca Armentano, Marta Lambiase, Alessandro Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy |
title |
Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
|
title_full |
Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
|
title_fullStr |
Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
|
title_full_unstemmed |
Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
|
title_short |
Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
|
title_sort | eye drop emulsion containing 0.1% cyclosporin (1 mg/ml) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616155/ https://www.ncbi.nlm.nih.gov/pubmed/31308622 http://dx.doi.org/10.2147/OPTH.S181811 |
work_keys_str_mv | AT nebbiosomarcella eyedropemulsioncontaining01cyclosporin1mgmlforthetreatmentofseverevernalkeratoconjunctivitisanevidencebasedreviewandplaceintherapy AT alisiludovico eyedropemulsioncontaining01cyclosporin1mgmlforthetreatmentofseverevernalkeratoconjunctivitisanevidencebasedreviewandplaceintherapy AT giovannettifrancesca eyedropemulsioncontaining01cyclosporin1mgmlforthetreatmentofseverevernalkeratoconjunctivitisanevidencebasedreviewandplaceintherapy AT armentanomarta eyedropemulsioncontaining01cyclosporin1mgmlforthetreatmentofseverevernalkeratoconjunctivitisanevidencebasedreviewandplaceintherapy AT lambiasealessandro eyedropemulsioncontaining01cyclosporin1mgmlforthetreatmentofseverevernalkeratoconjunctivitisanevidencebasedreviewandplaceintherapy |